According to Dr Won Park, Inha University Hospital, Korea, and lead investigator
of the PLANETAS study, «the challenge for biosimilars is to demonstrate similarity in
therapeutic effectiveness, safety and immunogenicity to their reference
product, not just biochemical and pharmacokinetic equivalence.»
As much as possible, you would want to get a flea control
product that can give you a fast onset
of action, a fast peak onset, and an extra-long
therapeutic effectiveness.